Qihao Medical completed tens of millions of RMB financing This article is edited by Maker Commune, and the material comes from Lieyun.com, 36Kr, etc. If you need to reprint, please indicate the source. Recently, Qihao Medical received tens of millions of RMB in Pre-A round of financing. This round of financing was invested by Tongrun Technology Investment (lead investment), and Instant Capital served as the exclusive financial advisor for this round of financing. According to the company's information, Jiangsu Qihao Medical Technology Co., Ltd. was established in June 2017. It is mainly engaged in the R&D, production and sales of high-end implanted interventional medical devices for ENT microtrauma. It is a high-start, high-tech medical Device technology companies. It is worth mentioning that the core team of Qihao Medical has extensive experience in R&D and sales. Pang Yonggang, Executive Director and General Manager of Qihao Medical, graduated from Beijing Normal University with a Doctor of Philosophy in Management. He has worked in Braun, Germany for 7 years, Johnson & Johnson in the United States for 4 years, and Shanghai Kailitai for 5 years, responsible for the clinical development and sales of Fangrun Plasma across the country. . Up to now, Qihao Medical has accepted 10 invention patents and 7 utility model patents. The company is developing clinical cooperation with well-known hospitals such as Peking Union Medical College Hospital, Beijing PLA General Hospital and Shanghai Xinhua Hospital. It is understood that this round of financing will be used to accelerate the completion of clinical trials of two core products of Qihao Medical-"Low-temperature Plasma Radio Frequency Surgery System" and "Fully Degradable Sinus Drug Stent", as well as the development, production and testing of other new products . Pang Yonggang, the founder of Qihao Medical, said: "Kaihao Medical is based on providing clinicians with a total solution for disease treatment, not a single product treatment method. Only when the product line is perfect, future marketing, technical support, and academic support can provide powerful In the face of the new market competition situation of high-volume procurement, bidding and bidding, multi-product portfolios and overall solutions have great bargaining advantages, quality assurance advantages and logistics cost advantages." Tongrun Technology Investment Li Dong, Zhu Min and Wang Weixing said: "Currently, domestic medical investment is still hot. How to maintain independent thinking and choose suitable investment targets is a test for every investment institution. Tongrun has not always paid attention to'hot Track’, but more interested in the layout has not yet been enthusiastically sought after, while domestic companies have the opportunity to catch up. In this regard, ENT meets our requirements. Qihao Medical has distinctive characteristics among many ENT companies , In other words, the product layout is relatively more comprehensive, and it is in line with the market's pain points. It has excellent reserves in the near, medium and long term. In the future, it can give full play to its market advantages through combination punches. As the exclusive financial adviser and long-term partner of this round of financing, Hao Fangran, Vice President of Instant Capital, believes: "Qihao Medical focuses on the fast-growing and explosive ENT equipment segmentation field, and works hard and quickly realizes product transformation and landing. , Demonstrating strong perseverance and long-term vision, such enterprises are more likely to be favored by investment institutions in the cold winter of capital.